

## Next Generation Cellular Therapeutic Technologies: Rapid Detection of Bacterial Contamination

Kai Nesemann, Maya Fuerstenau-Sharp, Caroline Paeschke Sartorius Stedim Biotech GmbH, D-37079 Goettingen, Germany Corresponding author: PCR@sartorius.com

Sterility is a critical quality attribute (CQA) of cellular therapeutics. Since microbial contamination of cell therapy products can potentially result in the deaths of the recipients, sterility testing is a critical component of the release testing for any cell therapy product. The current compendial sterility test takes 14 days before contamination can be ruled out with certainty, which is too long for short shelf life cellular therapeutics and especially for autologous cell therapies intended to treat terminally ill patients. As a result there is an increasing demand for growth-independent rapid assays. Therefore a detection system consisting of the highly efficient DNA extraction protocol Microsart<sup>®</sup> Bacteria Extraction followed by the real time PCR assay Microsart<sup>®</sup> ATMP Bacteria has been developed. A validation study was designed to evaluate the bacterial detection capability. The study was set up to meet requirements of the European Pharmacopeia chapter 5.1.6.



	Run 2	32.16	32.40	32.17	32.03	32.19	
50	Run 1	32.93	34.20	33.76	34.00	33.72	8/8
	Run 2	34.62	33.36	33.36	33.44	33.69	
10	Run 1	36.11	35.97	36.00	35.62	35.92	8/8
	Run 2	35.02	36.28	34.64	34.47	35.10	
5	Run 1	35.03	37.25	36.62	37.05	36.49	8/8
	Run 2	36.17	37.39	36.30	36.27	36.53	
2.5	Run 1	36.78	No Ct	37.05	No Ct	36.91	6/8
	Run 2	36.73	36.88	35.54	36.85	37.25	



## **Summary and Outlook**

The depicted scheme and results give an impression of the complexity of product validation required for a qPCR based bacterial detection kit for cellular therapeutics. In addition to the classic sterility testing, a rapid qPCR based detection of bacterial contamination contribute to a risk reduction and therefore contribute to patient safety.

A respective assay to detect fungal contamination using the same technology and temperature profile as the bacteria assay will complete the portfolio, enabling simultaneous results of total bacteria and fungi within the same PCR run, within 3 hours instead of weeks. A rapid detection of such contaminants in cellular therapeutics with short shelf lives and especially autologous cell therapies is urgently needed prior administration to terminally ill patients.